Disclosures for "Efficacy and Safety of Zilganersen, an Investigational RNA-targeted Antisense Therapy, in People Living with Alexander Disease: Results from a Pivotal Study"
-
Dr. Waldman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SwanBio. An immediate family member of Dr. Waldman has or had stock in Pfizer. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Roche/Genentech. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Calico. Dr. Waldman has received publishing royalties from a publication relating to health care. Dr. Waldman has received publishing royalties from a publication relating to health care.
-
Dr. Lynch has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vigil Neuroscience. Dr. Lynch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. The institution of Dr. Lynch has received research support from Ionis.
-
Prof. Tonduti has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Icometrix . Prof. Tonduti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Egetis.
-
The institution of Marjo Van Der Knaap, MD, PhD has received research support from Calico. The institution of Marjo Van Der Knaap, MD, PhD has received research support from Ionis.
-
Dr. Bernard has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Calico. Dr. Bernard has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Orchard Therapeutics. Dr. Bernard has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for N/A. The institution of Dr. Bernard has received research support from Canadian Institutes of Health Research. The institution of Dr. Bernard has received research support from Montreal Children's Foundation. The institution of Dr. Bernard has received research support from Yaya Foundation for 4H Leukodystrophy. The institution of Dr. Bernard has received research support from Fondation Les Amis d'Elliot. The institution of Dr. Bernard has received research support from Ionis. Dr. Bernard has a non-compensated relationship as a Member of the Scientific Advisory Board with Pelizaeus-Merzbacher Foundation that is relevant to AAN interests or activities. Dr. Bernard has a non-compensated relationship as a Member of the Medical and Scientific Advisory Board with United Leukodystrophy Foundation that is relevant to AAN interests or activities. Dr. Bernard has a non-compensated relationship as a Chair of the Medical and Scientific Advisory Board with United Leukodystrophy Foundation that is relevant to AAN interests or activities. Dr. Bernard has a non-compensated relationship as a Member of the Scientific and Clinical advisory Council with Yaya Foundation that is relevant to AAN interests or activities.
-
An immediate family member of Dr. Eichler has received personal compensation for serving as an employee of UpToDate. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atlas Venture. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leal Therapeutics. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orchard Tx. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis Therapeutics. The institution of Dr. Eichler has received research support from ASPA Therapeutics. The institution of Dr. Eichler has received research support from Abbvie. The institution of Dr. Eichler has received research support from Ionis Pharmaceuticals.
-
Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne Therapeutics. Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viking Therapeutics. Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Sampson has received research support from Marigold Foundation. Dr. Sampson has a non-compensated relationship as a Scientific Advisory Committee with Myotonic Dystrophy Foundation that is relevant to AAN interests or activities.
-
Dr. Zerem has nothing to disclose.
-
Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janseen. Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NerveGen. Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
-
Dr. Cunningham has nothing to disclose.
-
Dr. Bertini has received personal compensation for serving as an employee of Bambino Gesu' Children's Resesarch Hospital.
-
Dr. Hacohen has nothing to disclose.
-
Mr. Saito has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Nippon Shinyaku. The institution of Mr. Saito has received research support from Ionis Pharmaceuticals. Mr. Saito has received publishing royalties from a publication relating to health care.
-
Dr. Keller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Applied Therpeutics. Dr. Keller has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for United Leukodystrophy Foundation. The institution of Dr. Keller has received research support from CHOP/NIH. The institution of Dr. Keller has received research support from IONIS. The institution of Dr. Keller has received research support from Biomarin. The institution of Dr. Keller has received research support from Boehring-Ingelheim.
-
Dr. Vaia has nothing to disclose.
-
Dr. Kim has nothing to disclose.
-
Dr. Nagy has nothing to disclose.
-
Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viking Therapeutics. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bluebirdbio. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orpheris. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PRIME, Inc. The institution of Dr. Van Haren has received research support from Minoryx. The institution of Dr. Van Haren has received research support from bluebirdbio. Dr. Van Haren has a non-compensated relationship as a Board of Directors with ALD Connect that is relevant to AAN interests or activities. Dr. Van Haren has a non-compensated relationship as a Scientific Advisory Board with United Leukodystrophy Foundation that is relevant to AAN interests or activities.
-
Dr. van den Berg has nothing to disclose.
-
Ms. chen has received personal compensation for serving as an employee of Ionis Pharmaceuticals Inc.. An immediate family member of Ms. chen has received personal compensation for serving as an employee of University of Chicago. Ms. chen has stock in Ionis Pharmaceuticals Inc.. The institution of an immediate family member of Ms. chen has received research support from National Institute of Health. The institution of an immediate family member of Ms. chen has received research support from V Foundation. The institution of an immediate family member of Ms. chen has received research support from American Cancer Society.
-
Dr. Ruiz has stock in Ionis. Dr. Ruiz has stock in Amgen. Dr. Ruiz has stock in Bristol-Myers-Squibb.
-
Dr. Collins has received personal compensation for serving as an employee of Ionis Pharmaceuticals. Dr. Collins has stock in Ionis Pharmaceuticals.
-
Anne Smith has received personal compensation for serving as an employee of Ionis Pharmaceuticals. Anne Smith has stock in Ionis Pharmaceuticals.